Sep 18th, 2020 - Updates, guides, webinar series, recommendations, more.

Sep 18th, 2020 - This Webinar series has been organised with the aim to share the ESMO adapted recommendations for cancer patient management during the COVID-19 pandemic. These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients.

Sep 18th, 2020 - The core content of each COVID-19 adapted recommendation is presented in a user-friendly format ready for you to use in your own presentations, both to illustrate your own cases and research, as well as for educational purposes. Please note that while you may use slides individually from the sets for personal use, it is strictly forbidden to alter or hide any of the content, the ESMO logo, the ...

Sep 18th, 2020 - ESMO Virtual Congress 2020 Science Weekend Online Program

Sep 18th, 2020 - Abstract submission categories Basic science Biliary tract cancer, incl. cholangiocarcinoma Biomarkers (agnostic) Breast cancer, early stage Breast cancer, locally advanced Breast cancer, metastatic CNS tumours Colorectal cancer Developmental therapeutics Endocrine tumours Genitourinary tumours, prostate Genitourinary tumours, non-prostate Gynaecological cancers Haematological mal...

Sep 18th, 2020 - The COVID-19 pandemic has brought new challenges to clinical practice and research in oncology. ESMO is reporting on the current situation by news and KOLs experiences, and has gathered useful resources to keep medical oncologists updated.

Sep 18th, 2020 - EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY The leading professional organisation for medical oncology

Sep 18th, 2020 - With the new virtual platform, the aim is twofold: on one side to offer an experience which will be able to meet the needs of the many eager to find a fruitful learning opportunity; on the other, we are committed to still offer an engaging networking space, all delivered via state-of-the-art technology. Further information in this regard will be published progressively on this webpage soon.

Sep 18th, 2020 - The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community. The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

Sep 18th, 2020 - The ESMO Virtual Congress 2020 Programme is now online! The ESMO Virtual Congress 2020 will be the global stage for the exchange and debate of translational cancer science of excellence, first announcements of practice-changing data, and multidisciplinary must-have conversations set to spur transformative therapies against cancer.

Sep 18th, 2020 - ESMO Virtual Congress 2020: Frequently Asked Questions

Sep 17th, 2020 - In this page you can find the articles related to COVID-19 disease in the context of cancer care management as published in the ESMO flagship journal, the Annals of Oncology and the ESMO Open.

Sep 17th, 2020 - Bringing innovation to cancer patients. The ESMO Virtual Congress 2020 will present promising new developments aimed at improving cancer patient care. In response to the needs of the moment, the scientific programme will include a dedicated COVID-19 and cancer research track. Take part in Europe's most prestigious platform for oncology stakeholders.

Sep 17th, 2020 - These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients. The situation is evolving, and pragmatic actions may be required to deal with the challenges of treating patients, while ensuring their rights, safety and wellbeing.

Jul 30th, 2020 - We established an international consortium to discuss clinical evidence and to provide expert advice on statements related to cancer management during COVID-19 pandemics. The steering committee prepared ten working packages addressing significant clinical questions from diagnosis to surgery.

Sep 15th, 2020 - Histotype and grade of endometrial cancer (EC) are prognostic factors of nodal involvement and thus of survival. Preoperative biopsy (PB) and intraoperative frozen section (FS) are usually used to guide surgical staging on which the choice of adjuvant therapy will be based successively. The aim of this study was to assess the agreement rate between PB and FS with final diagnosis (FD) in a serie...

Sep 12th, 2020 - Glioblastoma (GBM) represents the most common primary malignancy of the central nervous system in adults, and remains a largely incurable disease. The elucidation of disease subtypes based on mutational profiling, gene expression and DNA methylation has so far failed to translate into improved clinical outcomes. However, new knowledge emerging from the subtyping effort in the IDH-wildtype setti...

Sep 11th, 2020 - Oncogenic gene fusions are hybrid genes that result from structural DNA rearrangements, leading to deregulated activity. Fusions involving the neuregulin-1 gene (NRG1) result in ErbB-mediated pathway activation and therefore present a rational candidate for targeted treatment. The most frequently reported NRG1 fusion is CD74-NRG1, which most commonly occurs in patients with invasive mucinous ad...

Sep 9th, 2020 - Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three poly (ADP-ribose) polymerase (PARP) inhibitors at the European Society for Medical Oncology (ESMO) 2019 Congress.1 The picture became a little clearer on April 29, 2020, however, when the U.S. Food and Drug Administration (FDA) approved the PARP inh...

Sep 9th, 2020 - The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta ­Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies evaluated different immunotherapy combinations, and in both, there were high response rates and de...